病毒性肝炎的基因治疗(2)
4 直接导入抗病毒基因
利用长效表达载体将IFN-α基因转入肝脏能够诱导病肝长期持续地产生IFN-α。研究显示一种表达IFN-α的腺病毒载体在小鼠模型中能够有效地防治病毒性肝炎。但是该长效载体在慢性病毒性肝炎动物模型中的疗效和毒性还有待更深入的研究。
5 展望
基因治疗是调节病变组织生物功能的强大工具，具有很强的可塑性，在肝炎防治中应用前景广阔。越来越多的实验室和临床研究结果明确地证明基因作为治療性药物将在未来的医疗领域中发挥越来越重要的作用。但是人们需要进行更多更深入的研究来评估基因治疗的潜力，不断改善治疗效果，同时不断降低其毒性作用。
参考文献
[1]Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature ,2004,431:343-9.
[2]Wu Y, Huang AL, Tang N, et al. RNA interference inhibits replication and expression of hepatitis B virus in mice. Zhonghua Yi Xue Za Zhi, 2005 ,85(9):630-4.
[3]Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep,2003 ,4(6):602 -8.
[4]Vidalin O, Fournillier A, Renard N, et al. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E 2 antigens. Virology ,2000,276:259-70.
[5]Bru?a-Romero O, Lasarte JJ, Wilkinson G, et al. Induction of cytotoxic T-cell response against hepatitis c virus structural antigens using a defective recombinant adenovirus. Hepatology,1997,25:470-7., http://www.100md.com(丁雯)
利用长效表达载体将IFN-α基因转入肝脏能够诱导病肝长期持续地产生IFN-α。研究显示一种表达IFN-α的腺病毒载体在小鼠模型中能够有效地防治病毒性肝炎。但是该长效载体在慢性病毒性肝炎动物模型中的疗效和毒性还有待更深入的研究。
5 展望
基因治疗是调节病变组织生物功能的强大工具，具有很强的可塑性，在肝炎防治中应用前景广阔。越来越多的实验室和临床研究结果明确地证明基因作为治療性药物将在未来的医疗领域中发挥越来越重要的作用。但是人们需要进行更多更深入的研究来评估基因治疗的潜力，不断改善治疗效果，同时不断降低其毒性作用。
参考文献
[1]Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature ,2004,431:343-9.
[2]Wu Y, Huang AL, Tang N, et al. RNA interference inhibits replication and expression of hepatitis B virus in mice. Zhonghua Yi Xue Za Zhi, 2005 ,85(9):630-4.
[3]Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep,2003 ,4(6):602 -8.
[4]Vidalin O, Fournillier A, Renard N, et al. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E 2 antigens. Virology ,2000,276:259-70.
[5]Bru?a-Romero O, Lasarte JJ, Wilkinson G, et al. Induction of cytotoxic T-cell response against hepatitis c virus structural antigens using a defective recombinant adenovirus. Hepatology,1997,25:470-7., http://www.100md.com(丁雯)